EMA Group Favors Naming SLS-005 an Orphan Drug for ALS
A committee with the European Medicines Agency favors designating Seelos Therapeutics‘ investigational therapy SLS-005 (trehalose) an orphan drug as a potential…
Articles by Forest Ray PhD
Medicare Adds Speech, Oral Therapy to Telehealth Services
Speech and oral therapy were added to covered services available by telemedicine for people with amyotrophic lateral sclerosis (ALS),…
Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS
Ionis Pharmaceuticals is opening a Phase 3 safety and efficacy trial of ION363 (jacifusen) in amyotrophic lateral sclerosis (ALS) patients…
First Patients Dosed in Phase 2 Trial of RT001
Retrotope has dosed the first patients in its recently-initiated Phase 2 clinical trial evaluating RT001 for the treatment…
PharmaTher Plans to Develop Ketamine as Potential ALS Treatment
Under an agreement with the University of Kansas, PharmaTher has gained exclusive worldwide rights to develop and…
NurOwn Showed No Benefit Over Placebo in Trial, FDA Says
The small difference in treatment responses among amyotrophic lateral sclerosis (ALS) patients receiving NurOwn versus a placebo in a…
PrimeC Safe, Well-tolerated; Earns US Patent Allowance
PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and showed signs…
Higher Suicide Risk Found for US Veterans With ALS
Military veterans with amyotrophic lateral sclerosis (ALS) are nearly four times as likely to commit suicide as vets without…
BrainStorm, FDA Discuss Plans for Manufacturing of NurOwn
BrainStorm Cell Therapeutics met with U.S. Food and Drug Administration (FDA) officials regarding its plans for a semi-automatic manufacturing…
ALS Groups Given $20K Grants by Cytokinetics to Support Outreach Work
Cytokinetics awarded two amyotrophic lateral sclerosis (ALS) patient advocacy organizations grants worth $20,000, in recognition of their efforts…